Clinical Trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Protocol Amendment History 5 changes
notable Enrollment increased: 408 -> 570 participants 2026-07-24
minor Trial arms changed: 10 -> 12 2026-07-24
notable Trial sites expanded: 36 -> 39 locations 2026-07-24
notable Primary completion pushed: 2027-01-13 -> 2029-05-03 2026-07-24
minor Completion pushed: 2027-01-13 -> 2029-05-03 2026-07-24
Trial Details
NCT Number NCT05836324
Lead Sponsor Incyte Corporation
Conditions Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Enrollment 570 participants
Start Date 2023-07-24
Primary Completion 2029-05-03 (estimated)
Study Completion 2029-05-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-23